New Stock News | Weigene Pharmaceuticals Submits Application to Hong Kong Stock Exchange

According to financial news app, China Fortune, it was revealed by the Hong Kong Stock Exchange on November 7th that Vechain International Holdings Limited (Vechain Pharmaceuticals) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Huatai International as its exclusive sponsor. According to the prospectus, Vechain Pharmaceuticals is a leading comprehensive pharmaceutical company in China that focuses on the treatment of kidney and blood diseases, with integrated strength in drug development, production, and commercialization. Vechain Pharmaceuticals is committed to addressing the huge unmet clinical needs in the treatment of kidney and blood diseases and other major diseases by providing innovative and valuable treatment solutions.